跳轉至內容
Merck
全部照片(1)

文件

557502

Sigma-Aldrich

Ro-20-1724

≥98% (TLC), solid, cAMP phosphodiesterase inhibitor, Calbiochem

同義詞:

Ro-20-1724, 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C15H22N2O3
CAS號碼:
29925-17-5
分子量：:
278.35
MDL號碼:
MFCD00077397
分類程式碼代碼:
12352200
NACRES:
NA.77

product name

Ro-20-1724, A cell-permeable, selective inhibitor of cAMP-specific phosphodiesterase (PDE IV; IC₅₀ = 2 µM).

品質等級

100

化驗

≥98% (TLC)

形狀

solid

製造商／商標名

Calbiochem®

儲存條件

OK to freeze

顏色

white

溶解度

DMSO: 20%
ethanol: 4%

運輸包裝

ambient

儲存溫度

10-30°C

InChI

1S/C15H22N2O3/c1-3-4-7-20-14-9-11(5-6-13(14)19-2)8-12-10-16-15(18)17-12/h5-6,9,12H,3-4,7-8,10H2,1-2H3,(H2,16,17,18)

InChI 密鑰

PDMUULPVBYQBBK-UHFFFAOYSA-N

一般說明

A cell-permeable, selective inhibitor of cAMP-specific phosphodiesterase (PDE IV; IC50 = 2 µM). Inhibits superoxide generation and arachidonic-induced platelet aggregation. Also inhibits fMLP-induced neutrophil adhesion to vascular endothelial cells.
Selective inhibitor of cAMP-specific phosphodiesterase (PDE IV, IC50 = 2 µM). Inhibits superoxide generation and arachidonic-induced platelet aggregation. Also inhibits fMLP-induced neutrophil adhesion to vascular endothelial cells.

生化／生理作用

Cell permeable: yes
Primary Target
PDE IV
Product does not compete with ATP.
Reversible: no
Target IC50: 2 µM against PDE IV

警告

Toxicity: Irritant (B)

其他說明

Derian, C.K., et al. 1995. J. Immunol. 154, 308.
Rubin, L.L., et al. 1991. J. Cell Biol.115, 1725.
Lad, P.M., et al. 1985. Biochim. Biophys. Acta 846, 286.
Bergstrand, H., et al. 1977. Mol. Pharmacol.13, 38.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Mohammad Keyvanloo Shahrestanaki et al.
Research in pharmaceutical sciences, 14(2), 107-114 (2019-10-18)
Diabetes incidence showed ascending trends in recent years indicating urgent need for new therapeutic agents. Extracellular adenosine signaling showed promising results. However, role of its A3 receptor in pancreatic β-cells proliferation and insulin secretion is not well established. Thus, we
Pieter J Gaillard et al.
Methods in molecular biology (Clifton, N.J.), 437, 161-175 (2008-03-29)
Drug delivery across the blood-brain barrier (BBB) is a major obstacle for the development of effective treatments of many central nervous system disorders. Sophisticated cell culture models of the BBB have helped us to identify, characterize, and validate a novel
Alejandro Sánchez-Melgar et al.
Frontiers in neuroscience, 15, 702817-702817 (2021-09-21)
Gliomas are the most common and aggressive primary tumors in the central nervous system. The nucleoside adenosine is considered to be one major constituent within the tumor microenvironment. The adenosine level mainly depends on two enzymatic activities: 5'-nucleotidase (5'NT or

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務